Skip to main content
. 2016 Sep 21;7:12878. doi: 10.1038/ncomms12878

Figure 4. Immunoactivation with IL-2 and construct administration in vivo.

Figure 4

(a) Total splenocyte counts in AJ mice after a five-day course of 200,000 IUe of wtIL-2 (blue), mutIL-2 (green) and OMCP-mutIL-2 (red). (b) NK cell expansion and activation after wtIL-2, mutIL-2, OMCP-mutIL-2, high dose wtIL-2, high dose mutIL-2 and wtIL-2/anti-IL-2 complexes measured by cell counts in the spleen (top) and KLRG1 upregulation (bottom). Expansion of splenocytes (c) and NK cells (d) in C57BL/6 mice treated with 750,000 IUe of cytokine or construct. All graphs represent an average cell count ± s.e.m. from 5–10 mice per group performed as 4–7 separate experiments for each strain of mice. Comparison performed by unpaired t-test between groups as indicated by the lines. ns P>0.05; *P<0.05; **P<0.01; ***P<0.001; black=saline; blue=wtIL-2, red=OMCP-mutIL-2, green=mutIL-2, turkoise=wtIL-2 complexed to anti-IL-2.

HHS Vulnerability Disclosure